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ABSTRACT Only native polypeptides are released from the endoplasmic reticulum (ER) to be 
transported at the site of activity. Persistently misfolded proteins are retained and eventually 
selected for ER-associated degradation (ERAD). The paradox of a structure-based protein 
quality control is that functional polypeptides may be destroyed if they are architecturally 
unfit. This has health-threatening implications, as shown by the numerous “loss-of-function” 
proteopathies, but also offers chances to intervene pharmacologically to promote bypassing 
of the quality control inspection and export of the mutant, yet functional protein. Here we 
challenged the ER of human cells with four modular glycopolypeptides designed to alert lu-
minal and membrane protein quality checkpoints. Our analysis reveals the unexpected col-
laboration of the cytosolic AAA-ATPase p97 and the luminal quality control factor UDP-
glucose:glycoprotein glucosyltransferase (UGGT1) in a novel, BiP- and CNX-independent 
checkpoint. This prevents Golgi transport of a chimera with a native ectodomain that passes 
the luminal quality control scrutiny but displays an intramembrane defect. Given that human 
proteopathies may result from impaired transport of functional polypeptides with minor 
structural defects, identification of quality checkpoints and treatments to bypass them as 
shown here upon silencing or pharmacologic inhibition of UGGT1 or p97 may have important 
clinical implications.
INTRODUCTION
The protein quality control machineries operating in the mamma-
lian endoplasmic reticulum (ER) lumen examine soluble proteins or 
the ectodomain of membrane polypeptides in search of nonnative 
determinants such as hydrophobic patches, unpaired cysteine 
residues, and nonnative peptidyl-prolyl bonds. Most polypeptides 
entering the ER are modified with core oligosaccharides (glucose3-
mannose9-N-acetylglucosamine2-), which are covalently bound 
to asparagine side chains (N-linked glycosylation). Their processing 
is a crucial part of protein quality control. Cycles of deglucosyla-
tion/reglucosylation catalyzed by glucosidase II and UDP-
glucose:glycoprotein glucosyltransferase (UGGT1) determine re-
tention in the calnexin (CNX) chaperone system and promote 
formation of native disulfide and peptidyl-prolyl bonds (Caramelo 
and Parodi, 2008). Complete deglucosylation allows secretion from 
the ER and transport at the site of activity. Extensive demannosyla-
tion catalyzed by members of the glycosyl hydrolase 47 family of 
α1,2-mannosidases (Olivari and Molinari, 2007) triggers selection 
for dislocation into the cytosol and proteasome-mediated clear-
ance (ER-associated degradation [ERAD]; Brodsky, 2012; Braakman 
and Hebert, 2013; Merulla et al., 2013).
Structural defects that may prevent polypeptide transport 
through the secretory pathway include potentially charged (ionizable) 
residues in the intramembrane domain of membrane-anchored 
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α1ATcD6A chimeras (Figure 1A). Our study 
reveals a novel protein quality checkpoint, 
which is alerted to prevent secretion of a 
polypeptide that passes the luminal quality 
control scrutiny by BiP and CNX but con-
tains an intramembrane ionizable residue. 
This checkpoint is bypassed upon p97 or 
UGGT1 silencing or pharmacologic p97 
inactivation.
RESULTS
The intramembrane ionizable residue 
does not impair membrane anchoring
To alert and study protein quality check-
points of the human early secretory pathway, 
we generated four model chimeric proteins 
by fusing α1AT, a serine protease inhibitor 
secreted from hepatocytes (Perlmutter, 
2011), or NHK, a disease-causing, folding-
defective variant thereof (Sifers et al., 1988), 
with two different membrane anchors. The 
first anchor corresponds to the TM and cyto-
solic domains of CD3δ and contains a desta-
bilizing ionizable aspartic acid residue at po-
sition 6 of the intramembrane region 
(chimeras α1ATc and NHKc), which is re-
placed by an alanine in the second anchor 
(chimeras α1ATcD6A and NHKcD6A; Figure 
1A). Because ionizable residues in single-pass membrane-anchored 
proteins increase the free energy of membrane integration (ΔGTM) to 
levels that may prevent insertion of newly synthesized polypeptides 
in the lipid bilayer (Shin et al., 1993; Fayadat and Kopito, 2003; Hessa 
et al., 2007; Feige and Hendershot, 2013), we first controlled mem-
brane association of the four chimeras used in this study. To this end, 
we performed subcellular fractionation to separate cytosolic (Supple-
mental Figure S1A, lanes 1 and 2, p97 as marker), luminal (lanes 3 
and 4, calreticulin [CRT]), and membrane-associated proteins (lanes 
5 and 6, thioredoxin-related transmembrane protein 1 [TMX1]). Effi-
cient membrane integration was confirmed (Figure 1, B–E, lane 5), 
and only a negligible fraction of the four chimeras was detected in 
the cytosolic (lane 1) or luminal fractions (lane 3), unless cells were 
exposed to the proteasome inhibitor PS341 (lanes 2, 4, and 6; see 
later discussion). This was in good agreement with the calculated 
ΔGTM (http://dgpred.cbr.su.se), which predicts efficient membrane 
integration for the ionizable CD3δ TM, which anchors NHKc and 
α1ATc at the membrane (ΔGTM = −0.76), and for the nonionizable 
CD3δ TM, which anchors NHKcD6A and α1ATcD6A (ΔGTM = −2.26).
An ionizable residue in the TM domain determines higher 
extractability from the lipid bilayer and faster disposal of a 
folding-defective ectodomain
NHK is a soluble ERAD substrate, which is dislocated across the ER 
membrane and degraded by cytosolic proteasomes (Liu et al., 
1997). Addition of a membrane anchor with or without an ionizable 
residue in the TM domain (NHKc and NHKcD6A, respectively; Figure 
1A) did not change the fate of the folding-defective ectodomain. In 
fact, both chimeras were efficiently cleared from the ER (Figure 2, A 
and B, lanes 1–5, and C). To study this, HEK293 cells expressing 
NHKc or NHKcD6A were pulsed with [35S]methionine and cysteine 
and chased for up to 120 min in the absence of radioactivity. The 
decay of the immunoisolated, radiolabeled chimeras was quantified 
after their separation in SDS–PAGE (Figure 2, A–C). NHKc had a 
polypeptides (Klausner et al., 1990). Such residues (aspartic and glu-
tamic acids, lysines, and arginines) lower the hydrophobicity of 
transmembrane (TM) regions (Hessa et al., 2007) and play crucial 
roles in biogenesis of several oligomeric signaling complexes by in-
suring retention of orphan subunits to complete complex assembly 
and degradation of subunits produced in nonstoichiometric amount 
(Klausner et al., 1990; Call and Wucherpfennig, 2005; Feng et al., 
2006; Tyler et al., 2012). Mutations that introduce ionizable residues 
in the intramembrane domain have been linked to loss-of-function 
diseases such as idiopathic epilepsy (Cossette et al., 2002; Gallagher 
et al., 2005) or Ehlers–Danlos syndrome (Bin et al., 2014), in which 
an alanine- or glycine-to–aspartic acid mutation in the TM domain 
inappropriately tags for degradation functional γ-aminobutyric acid 
type A (GABAA) receptors or ZIP13 proteins, respectively. Idiopathic 
epilepsy and Ehlers–Danlos syndrome are only two of the hundreds 
of loss-of-function diseases in which the quality control operating in 
the secretory pathway, which is based on detection of structural de-
fects, inappropriately prevents transport of functional polypeptides 
at their final destination. In such cases, the therapeutic interventions 
that enhance folding, stabilize the mutated polypeptide, or promote 
bypassing of the transport block are highly sought after (Powers 
et al., 2009; Guerriero and Brodsky, 2012; Noack et al., 2014).
To understand in more detail the mechanisms regulating protein 
quality control in the secretory pathway, to understand the conse-
quences of the presence of intramembrane ionizable residues, and 
to evaluate pharmacologic interventions that promote secretion of 
inappropriately retained proteins, we monitored the fate of model 
type I membrane proteins for which a folding-defective (null Hong 
Kong variant [NHK] of human α1-antitrypsin [α1AT]) or a folding-
competent ectodomain (α1AT) were fused to the C-terminal domain 
of CD3δ. This domain contains a naturally occurring integration-
competent intramembrane region with an ionizable aspartic acid 
residue at position 6 (model chimeras NHKc and α1ATc), which was 
replaced by an uncharged alanine residue in the NHKcD6A and 
FIGURE 1: Chimeras used in this study. (A) The soluble folding-defective NHK or the folding-
competent α1AT were fused with the transmembrane domain of CD3δ carrying an aspartic acid 
residue (–) in the intramembrane domain to generate the NHKc and α1ATc chimeras. The 
aspartic acid was replaced by an alanine in the NHKcD6A and α1ATcD6A chimeras. (B) Subcellular 
localization of NHKc in untreated cells (–) or in cells exposed to the proteasome inhibitor PS341 
(+). (C) Same as B, for NHKcD6A. (D) Same as B, for α1ATc (I, immature form of the protein). 
(E) Same as B for α1ATcD6A (I, immature; M, mature).
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polypeptide band (I for immature; Figure 3A, lanes 1–5) and a very 
faint polypeptide with slower electrophoretic mobility appearing 
at longer chase times (M for mature; Figure 3A, lanes 4 and 5). In 
the case of α1ATcD6A, the fast-migrating polypeptide shown with I 
was efficiently converted, starting at 30 min of chase, into the 
slowly migrating M band (Figure 3B, lanes 2–5). Reduction in a 
glycoprotein’s electrophoretic mobility occurs upon release of na-
tive proteins from the ER and arrival in the Golgi compartment, 
where N-linked oligosaccharides are modified to become much 
larger and resistant to EndoH cleavage (Rothman et al., 1984). An 
EndoH assay confirmed that α1ATc oligosaccharides remained 
EndoH sensitive throughout the chase (Figure 3, C and E), an indi-
cation that this protein was not delivered to the Golgi compart-
ment. In contrast, α1ATcD6A oligosaccharides became resistant to 
EndoH cleavage (Figure 3, D and E), implying that this chimera 
was efficiently transported to the Golgi. The different intracellular 
fate of these two chimeras was confirmed in IF. Both proteins co-
localized poorly with the ER marker CNX (Figure 3, F and I) and, 
more significantly, especially α1ATcD6A, with intermediate com-
partment/Golgi markers such as βCOP (Figure 3, G and J). In 
agreement with the biochemical analysis showing that only 
α1ATcD6A displays EndoH-resistant oligosaccharides (Figure 3, D 
and E), this chimera showed a substantial colocalization with the 
Golgi marker giantin (Figure 3K), whereas α1ATc was virtually ex-
cluded from the Golgi (Figure 3H).
half-life of ∼60 min (Figure 2, A, lanes 1–5, and C), which was sub-
stantially prolonged by the proteasomal inhibitor PS341, as ex-
pected for ERAD substrates (Figure 2A, lane 6). Replacement of the 
intramembrane ionizable aspartic acid with an alanine delayed the 
decay of NHKcD6A (half-life of ∼90 min; Figure 2, B, lanes 1–5, and 
C). Consistent with their retention in the ER during preparation for 
ERAD, both NHKc and NHKcD6A displayed endoglycosidase H 
(EndoH)–sensitive oligosaccharides (Figure 2D) and colocalized with 
the ER marker CNX in immunofluorescence (IF; Figure 2E).
Analysis of the subcellular compartmentalization of the misfolded 
proteins upon inactivation of the proteasomes revealed the substan-
tial accumulation of partially and fully deglycosylated NHKc in the cell 
cytosol (Figure 1B, lane 2, and Supplemental Figure S1B) to a much 
larger extent that what was observed for NHKcD6A (Figure 1C, lane 2, 
and Supplemental Figure S1B). This is consistent with an enhanced 
extractability from the lipid bilayer of the folding-defective chimera 
displaying an ionizable residue in the intramembrane space.
An ionizable residue in the TM domain prevents Golgi 
transport of the folding-competent α1AT ectodomain
The foregoing pulse-chase analysis was also used to determine 
the fate of the chimeras displaying the folding-competent α1AT 
ectodomain tethered at the ER membrane with an anchor contain-
ing (α1ATc) or not containing (α1ATcD6A) the ionizable aspartic 
acid residue. Analysis of radiolabeled α1ATc revealed a major 
FIGURE 2: The ionizable residue in the TM domain accelerates disposal of the folding-defective ectodomain. (A) Stable 
HEK293 cells expressing NHKc were radiolabeled and chased for up to 120 min without (lanes 1–5) or with the 
proteasome inhibitor PS341 (lane 6). (B) Same as A, for NHKcD6A. (C) Quantification of NHKc and NHKcD6A decay. 
Means and SDs are relative to three independent experiments. (D) Normalized amounts of metabolically labeled NHKc 
and NHKcD6A subjected to EndoH treatment. R, EndoH resistant; S, EndoH sensitive. (E) IF analysis showing 
colocalization of NHKcD6A and NHKc with the ER marker CNX in HEK293 cells. The chimeras were visualized with an 
anti-HA tag (left) and CNX with a polyclonal antibody recognizing the endogenous protein (middle). Right, merge. Scale 
bars, 10 μm.
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(Figure 4A, middle). This allows distinction of polypeptides display-
ing nonglucosylated oligosaccharides, for which the mobility shift 
upon JBαM treatment is similar to the shift caused by EndoH treat-
ment (Figure 4A, right), from polypeptides displaying glucosylated 
oligosaccharides, which are characterized by a smaller shift in elec-
trophoretic mobility upon JBαM treatment (Hebert et al., 1995). 
JBαM treatment performed on NHKc immediately after synthesis 
(10-min chase, Figure 4B, lanes 1 and 2) or 120 min after synthesis 
(lanes 3 and 4) caused a smaller shift in electrophoretic mobility than 
EndoH treatment (lanes 5 and 6). Hence, throughout the chase, 
NHKc mannoses were protected from complete removal by JBαM. 
This shows that NHKc is persistently reglucosylated by the UGGT1 
or fails to be efficiently deglucosylated by the glucosidase II 
Chimeras with folding-defective ectodomains are 
persistently reglucosylated and show prolonged association 
with the ER retention-factors CNX and BiP
Before selection for ERAD, folding-defective polypeptides are re-
tained in the ER upon association with CNX and BiP (Molinari et al., 
2002). Here the quality control factor UGGT1 plays a crucial role by 
persistently reglucosylating the oligosaccharides displayed on mis-
folded conformers, thereby preventing their release from the CNX 
chaperone system (Caramelo and Parodi, 2008). Persistent protein 
glucosylation is assessed by a jack bean α-mannosidase (JBαM) as-
say. In this assay, JBαM removes eight mannoses from deglucosy-
lated oligosaccharides (Figure 4A, left) but only five from oligosac-
charides where branch A is protected by a terminal glucose residue 
FIGURE 3: The ionizable residue in the TM domain retains the native ectodomain in a pre-Golgi compartment. 
(A) Stable cells expressing α1ATc were radiolabeled and chased for up to 120 min. The fast- and slow-migrating α1ATc 
are shown (I, immature; M, mature). (B) Same as A, for α1ATcD6A. (C) Equal amounts of metabolically labeled α1ATc were 
subjected to EndoH treatment. R, EndoH resistant; S, EndoH sensitive. (D) Same as C, for α1ATcD6A. (E) Kinetics of 
acquisition of EndoH-resistant N-glycans. (F) IF analysis showing the colocalization of α1ATc with the ER marker CNX. 
(G) Same as F, for the ER-Golgi intermediate compartment (ERGIC) marker βCOP. (H) Same as F, for the Golgi marker 
giantin. (I) Same as F, for α1ATcD6A. (J) same as G, for α1ATcD6A. (K) Same as H, for α1ATcD6A. Scale bars, 10 μm.
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Pharmacologic inactivation of p97 promotes 
α1ATc transport to the Golgi
To characterize the protein quality checkpoint preventing Golgi 
transport of α1ATc, we exposed cells for 4 h to low temperature 
(30°C), chemical chaperones (glycerol), or proteasomal (PS341) or 
p97 inhibitors (N2,N4-dibenzylquinazoline-2,4-diamine [DBeQ]), that 
is, to treatments that bypass retention-based quality control of dis-
ease-related polypeptides such as the cystic fibrosis conductance 
regulator, dystrophin, GABA receptor, ZIP13, and other mutant 
polypeptides, thereby alleviating disease phenotypes (Denning 
et al., 1992; Brown et al., 1996; Bonuccelli et al., 2003; Chou et al., 
2011; Bin et al., 2014; Han et al., 2015). Only cell treatment with 
DBeQ substantially enhanced α1ATc secretion to the Golgi, as 
shown by the appearance of the mature (M in Figure 5, A, lane 6, 
and B, lane 2 and arrow in lane 5), EndoH-resistant form of α1ATc 
(Figure 5B, lane 6). IF analysis confirmed that in cells exposed to 
DBeQ, α1ATc escapes retention-based quality control (Figure 5C) 
and travels to the Golgi compartment (Figure 5D and quantifica-
tion). It is worth mentioning that α1ATc retention was not affected 
by the inactivation of access to the CNX chaperone system with 
castanospermine (CST; Figure 5A, lane 4), a specific inhibitor of glu-
cosidase I and glucosidase II (Hammond et al., 1994).
To evaluate the selectivity of DBeQ, we compared the fate of 
NHKcD6A and NHKc (subjected to the conventional ER quality con-
trol), α1ATcD6A (efficiently exported to the Golgi), and α1ATc 
(halted by the DBeQ-sensitive checkpoint) in mock-, PS341-, or 
(arrowheads in Figure 4B, lanes 2 and 4, show where deglucosylated 
NHKc would run upon JBαM treatment). Consistent with the fold-
ing-defective state of their ectodomain, their colocalization with ER 
markers in IF (Figure 2E), and the persistent reglucosylation (Figure 
4B), NHKc and NHKcD6A showed a long-lasting association with the 
ER retention factors CNX (Figure 4, C and D, lanes 1–5) and BiP 
(lanes 6–10). They did not show detectable association with CRT 
(Supplemental Figure S2).
The poor colocalization of α1ATc and α1ATcD6A with ER chaper-
ones (Figure 3, F–I) shows that their folding-competent ectodomain 
passes luminal quality control and that the two chimeras are re-
leased from the ER. The JBαM assay confirmed the rapid degluco-
sylation of these chimeras, which allows complete oligosaccharide 
demannosylation already after a 10-min chase (the case of α1ATc is 
presented in Figure 4E, lanes 2 and 4). Consistently, both α1ATc and 
α1ATcD6A are rapidly released from CNX and BiP (Figure 4, F and G; 
they do not associate with CRT; Supplemental Figure S2) and from 
the ER (Figure 3, F and I). However, only α1ATcD6A pursues its trans-
port to the Golgi compartment (Figure 3K), where its oligosaccha-
rides acquire an EndoH-resistant status (Figure 3, B, D, and E). 
Evidently, the ionizable aspartic acid in the TM domain alerts a qual-
ity control device that prevents α1ATc export to the Golgi. This qual-
ity control system is clearly unrelated to the conventional ER reten-
tion–based quality control relying on UGGT1, CNX, and BiP, which 
regulates retention and eventually leads to disposal of the chimeras 
displaying the folding-defective ectodomain.
FIGURE 4: Glucosylation state and CNX/BiP binding. (A) Schematic representation of the products of JBαM (left and 
middle) and EndoH activities (right) on nonglucosylated (deG) and glucosylated (G) N-linked glycans. (B) Normalized 
amount of radiolabeled NHKc at 10- and 120- min chase times were subjected to JBαM (lanes 1–4) or EndoH treatment 
(lanes 5 and 6). (C) Radiolabeled CNX- (lanes 1–5) and BiP-associated (lanes 6–10) NHKc was immunoisolated from 
stable expressing HEK293 cells. First round of immunoprecipitation with anti-chaperone and second round with 
anti-chimera antibody. (D) Same as C, for NHKcD6A. (E) Same as B, for α1ATc. (F) Same as C, for α1ATc. (G) Same 
as C, for α1ATcD6A.
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unchanged electrophoretic mobility of the two chimeras with the 
folding-defective ectodomain confirmed that DBeQ did not impair 
the conventional CNX/BiP-mediated quality control that retains 
them in the ER (Figure 5E, bottom, lane 1 vs. lanes 2 and 3, and lane 
4 vs. lanes 5 and 6). DBeQ did not affect transport to the Golgi of 
α1ATcD6A, as shown by the unchanged attainment of the mature 
form of this protein (Figure 5E, bottom, lane 7 vs. lane 9), whereas it 
restored transport to the Golgi of α1ATc, as shown by the attain-
ment of the mature polypeptide form (Figure 5, A–D and E, bottom, 
arrow in lane 12). Thus, pharmacologic inactivation of p97 selec-
tively inactivates the checkpoint alerted by the chimera with the na-
tive ectodomain tethered at the membrane with an anchor contain-
ing an ionizable residue. Of interest, a similar alanine-to–aspartic 
acid mutation in the TM domain of the GABAA receptor is linked to 
defective surface transport of the mutant protein causing idiopathic 
epilepsy (Cossette et al., 2002; Gallagher et al., 2005). The disease 
DBeQ-treated cells. The chimeras were immunoisolated from cell 
lysates to evaluate changes in the association with the ER-reten-
tion factors CNX and BiP (Molinari et al., 2002; Figure 5E, top and 
middle), as well as variations in their electrophoretic mobility as a 
straightforward readout for glycoprotein release to the Golgi com-
partment (Figure 5E, bottom).
The newly synthesized, radiolabeled chimeras with the misfolded 
ectodomain show persistent association with CNX and BiP (Figure 
4, C and D), whereas the chimeras with the native ectodomain are 
rapidly released from the ER chaperones (Figure 4, F and G). Consis-
tently, at steady state, NHKcD6A and NHKc showed abundant asso-
ciation with the ER-retention factors (Figure 5E, top and middle, 
lanes 1–6), whereas α1ATcD6A and α1ATc associated poorly, if at all 
(lanes 7–12). PS341 and DBeQ had little effect on the coprecipita-
tion of CNX and BiP with NHKcD6A and NHKc (Figure 5E, top and 
middle, lane 1 vs. lanes 2 and 3, and lane 4 vs. lanes 5 and 6). The 
FIGURE 5: p97 and UGGT1 participate to the DBeQ-sensitive protein quality checkpoint. (A) α1ATc expressed in cells 
at 30°C or in cells exposed to glycerol, CST, PS341, or DBeQ. Only DBeQ allows production of the mature (M) form of 
α1ATc. (B) The slow-migrating α1ATc band is an EndoH-resistant form of the protein (R in lane 6). (C) Same as Figure 3H 
(lack of α1ATc colocalization with the Golgi marker giantin in mock-treated cells). (D) Same as C, in cells treated with 
DBeQ. α1ATc now colocalizes with giantin. The Manders coefficient shows the colocalization ratio between the green 
(α1ATc) and red channels (giantin) in mock- and DBeQ-treated cells (Bolte and Cordelieres, 2006). (E) Association of 
NHKcD6A, NHKc, α1ATcD6A, and α1ATc (used as baits; their amount was normalized) with CNX and BiP in mock-, PS341-, 
or DBeQ-treated cells. Bottom, asterisks show deglycosylated NHK chimeras accumulating upon proteasomal inhibition. 
(F) Same as E, in cells incubated with the chemical cross-linker DSP to stabilize weak associations (NHKc, α1ATc, and 
α1ATcD6A were used as bait). (G) Same as F, with UGGT1 as bait. (H) Only silencing of UGGT1 (lane 2) and p97 (lane 12) 
allows production of mature α1ATc. (I) Silencing of UGGT1 and p97 does not affect NHKc retention in the ER.
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delayed attainment of the native structure as a consequence of gene 
mutations (Lindquist and Kelly, 2011). Thus, the identification and 
comprehension at the molecular level of the quality checkpoints sur-
veying production of the human proteome is instrumental for design-
ing interventions that counteract their progression. Our data reveal a 
novel druggable quality checkpoint alerted when the polypeptide’s 
ectodomain fulfills quality control requirements for ER exit but dis-
plays other structural defects (in the chimera analyzed in this study, an 
intramembrane ionizable residue). By showing that cell exposure to 
DBeQ and silencing of p97 restore transport to the Golgi of α1ATc, 
our study identifies p97 as a pharmacologic target to treat loss-of-
function proteopathies and underscores the importance of develop-
ing function-specific inhibitors of p97 (Chou and Deshaies, 2011).
The cytosolic AAA ATPase p97 is a multifunctional protein 
(Yamanaka et al., 2012). It participates in a growing number of poorly 
characterized supramolecular complexes, some of which are in-
volved in ERAD, whereas others contain quality control and vesicu-
lar transport factors. The data presented here led us to exclude that 
transport to the Golgi of α1ATc is restored upon inactivation of the 
function of p97 in ERAD. In fact, proteasome inactivation does not 
lead to α1ATc secretion. Instead, it must be ascribed to a role of p97 
in regulating retention of proteins displaying intramembrane 
defects.
That silencing of p97 would restore α1ATc transport to the Golgi 
was expected because pharmacologic inactivation of p97 does. In 
contrast, that also UGGT1 silencing would restore α1ATc transport 
was at least partially surprising. In fact, α1ATc displays a native 
ectodomain whose oligosaccharides rapidly lose their terminal 
glucoses, is rapidly released from CNX, and is therefore most likely 
not a target of the enzymatic activity of UGGT1. The unperturbed 
retention of α1ATc in cells treated with CST (Figure 5A) confirms that 
generation of the monoglucosylated form of the α1ATc oligosac-
charides by the glucosidase I and glucosidase II and/or the persis-
tence of monoglucosylated forms engaging the ER-resident lectin 
chaperones upon UGGT1 activity is dispensable for the tightness of 
this novel quality control checkpoint. Nevertheless, UGGT1 cycles in 
post-ER boundaries (Zuber et al., 2001; Mezzacasa and Helenius, 
2002; Gilchrist et al., 2006), might participate in p97-containing su-
pramolecular complexes (Haines et al., 2012), and, as our data im-
ply, participates in DBeQ-sensitive complexes that control α1ATc 
retention. Intervention of p97 and of the UGGT1 in the protein qual-
ity checkpoint described in this work seems to elude their conven-
tional functions of major components of the ERAD machinery and 
the CNX cycle, respectively.
The UGGT1/p97 checkpoint complex must contain additional 
components and, possibly, one or more membrane-spanning 
proteins that bridge the cytosolic p97 and the luminal UGGT1 
(Figure 6). Like p97, the multispanning protein BAP31 is involved in 
ERAD (Wang et al., 2008) but also in vesicular transport in the early 
secretory pathway (Bell et al., 2001; Wakana et al., 2008). Signifi-
cantly, BAP31 shows preferential action on proteins characterized by 
the presence of ionizable residues in the TM domain (Geiger et al., 
2011). As such, BAP31 was a likely candidate to play a role in this 
novel, DBeQ-sensitive protein quality checkpoint that prevents 
α1ATc transport to the Golgi. However, BAP31 silencing did not re-
store transport to the Golgi of α1ATc (Figure 5H, lane 8). This shows 
that the residual amount (Supplemental Figure S3) of this very abun-
dant protein warrants retention of α1ATc or that an elusive, surro-
gate retention factor can intervene to replace BAP31. Similarly, si-
lencing of several other factors did not reestablish α1ATc transport 
to the Golgi (Figure 5H). Here as well, these factors are not involved 
in the DBeQ-sensitive checkpoint, their silencing was not efficient 
phenotype is alleviated by pharmacologic inactivation or silencing 
of p97. The recover in mutant GABAA receptor secretion has been 
attributed to the inhibition of the p97 function in ERAD (Han et al., 
2015). However, as in the case of α1ATc (Figures 5, A, lane 4, and E, 
lane 11), proteasome inhibition does not restore secretion of the 
mutant GABAA receptor. This leads us to postulate that inhibition of 
a role of p97 in quality control, rather than in ERAD, may play a role 
in recovering from loss-of-function diseases as well.
Pharmacologic inactivation of p97 restores transport to the 
Golgi of α1ATc by promoting α1ATc dissociation from p97 
and UGGT1
To confirm the involvement of the DBeQ target (i.e., p97) and verify 
possible involvement in the checkpoint preventing α1ATc transport 
to the Golgi of the quality control factor UGGT1, which cycles in 
post-ER boundaries (Zuber et al., 2001; Mezzacasa and Helenius, 
2002; Gilchrist et al., 2006) and participates in p97-containing com-
plexes (Haines et al., 2012), we analyzed NHKc, α1ATc, and α1ATcD6A 
associations with p97 and UGGT1 in the presence of the chemical 
cross-linker dithiobis succinimidyl propionate (DSP) to stabilize weak 
interactions. This test showed that NHKc and α1ATc (Figure 5F, lanes 
1–4), but not α1ATcD6A (lanes 5 and 6), entered complexes with both 
quality control factors (Figure 5F). Cell incubation with DBeQ did not 
significantly affect the association of p97 and UGGT1 with the ERAD 
substrate NHKc (lane 1 vs. lane 2), but it substantially decreased the 
coprecipitation of p97 and UGGT1 with α1ATc (lane 3 vs. lane 4). We 
postulate that in the case of NHK, UGGT1 regulates the reglucosyla-
tion that prolongs CNX association, and p97 intervenes in mem-
brane extraction of this ERAD substrate from the ER. In the case of 
α1ATc, which is rapidly released from CNX and is not degraded, the 
two quality control factors might participate in a novel functional 
retention complex preventing α1ATc secretion. Of note, p97 and 
UGGT1 have been identified as major interactors of the UBXD1 
adaptor protein (Haines et al., 2012) as an indication that they might 
coexist in functional complexes. Even though we did not detect 
UBXD1 among the α1ATc interactors (unpublished data), the immu-
noisolation of endogenous UGGT1 revealed the coprecipitation of 
p97 (Figure 5G). DBeQ did not disassemble the UGGT1:p97 com-
plex, as shown by the unchanged presence of p97 in immunocom-
plexes isolated with UGGT1 as bait (Figure 5G, middle, lane 2 vs. 
lane 3). Instead, the pharmacologic inactivation of p97 caused α1ATc 
release from the two retention factors (Figure 5G, bottom, lane 2 
vs. lane 3), thus restoring transport of this chimera to the Golgi.
p97 and UGGT1 silencing selectively restores transport 
to the Golgi of α1ATc
Silencing the expression of a series of early secretory pathway pro-
teins involved in quality control, in ERAD, or in vesicular transport 
revealed that only p97 and UGGT1 silencing correlated with the 
complex modification of oligosaccharides, showing transport of 
α1ATc to the Golgi compartment (Figure 5H, lanes 2 and 12, and 
Supplemental Figure S3). Silencing of p97 and of UGGT1 did not 
affect the ER retention of the chimeras displaying the misfolded ect-
odomain (Figure 5I). For p97, this is consistent with the fact that 
pharmacologic p97 inactivation did not interfere with conventional, 
retention-based ER quality control (Figure 5E, bottom, lanes 3 and 
6, showing the lack of mature NHKcD6A and NHKc forms in cells 
treated with DBeQ).
DISCUSSION
Human proteopathies may result from inappropriate elimination 
of functional polypeptides displaying minor structural defects or 
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FIGURE 6: The chimeras analyzed in this study and their fate. (A) The chimeras with the misfolded ectodomain 
(NHKcD6A and NHKc) are retained in the ER by the conventional quality control relying on UGGT1, CNX, and BiP 
intervention. These proteins are eventually destined to ERAD. (B) The chimera with the native ectodomain, 
characterized by an ionizable residue in the TM (α1ATc), fulfills the quality control requirement for release from CNX and 
BiP, but its transport to the Golgi is halted upon p97 and UGGT1 intervention. This protein quality checkpoint is 
bypassed upon pharmacologic inhibition of p97 or silencing of p97 or UGGT1 expression. (C) The folding-competent 
chimera (α1ATcD6A) is efficiently transported to the Golgi compartment.
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in HEK293 cells plated at 50–60% confluence on polylysine-coated 
3.5-cm Petri dishes. Cells were cotransfected with siRNA duplex (50 
pmol/dish; Ambion, Lucerne, Switzerland) and the expression plas-
mid of interest (0.5 μg/dish) using Lipofectamine 2000 (Invitrogen, 
Lucerne, Switzerland) according to the instructions of the manufac-
turer. Experiments were performed 48 h after transfection.
Metabolic labeling, immunoprecipitations, Western blots, 
and analysis of data
HEK293 cells transiently transfected (18 h after transfection) and 
stable cell lines were pulsed with 0.05 mCi of [35S]methionine/
cysteine mix and chased for the indicated time points with DMEM 
supplemented with 5 mM cold methionine and cysteine. Cell lysates 
were prepared by solubilization of cells with ice-cold 2% 3-[(3-chol-
amidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS; or 
RIPA) in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid–buff-
ered saline (HBS) and 20 mM N-ethylmaleimide (NEM) and then 
centrifuged 10 min at 10,000 × g. Native immunoprecipitations 
were performed by adding Protein A beads (Sigma-Aldrich; 1:10 
[wt/vol] swollen in HBS) and the selected antibody to cell lysates. 
Incubations were performed for 2 h at 4°C. The immunoprecipitates 
were extensively washed (3× 10 min) with 0.5% CHAPS in HBS or 
0.5% Triton X-100, resuspended in sample buffer, incubated at 65°C 
for 10 min, and separated in SDS–PAGE. To assess chimeras asso-
ciation with CNX and BiP, after immunoisolation of the ER chaper-
ones with the specific antibodies, proteins were denatured with 1% 
SDS and incubated at 65°C for 10 min, and 1% Triton X-100 was 
added to the samples. The supernatant obtained after centrifuga-
tion (2 min at 10,000 × g) was used for immunoprecipitation with 
anti-HA. Relevant bands were quantified by Image Quant software 
(Molecular Dynamics). Gels were also exposed to BioMax (Kodak) 
films and scanned with an AGFA scanner. For EndoH (New England 
Biolabs, Allschwil, Switzerland) treatment, immunoisolated chimeras 
were incubated for 2 h at 37°C. Samples were then analyzed in re-
ducing SDS–PAGE. Western blots were performed with blocking 
polyvinylidene difluoride (PVDF) membranes with 10% (wt/vol) milk 
(Bio-Rad, Cressier, Switzerland) and using primary antibodies at 
1:1000 to 1:3000 dilution. Secondary antibodies were horseradish 
peroxidase conjugated and used at 1:20,000 to 1:40,000 dilution. 
The Luminata Forte ECL detection system was from Millipore 
(Schaffhausen, Switzerland), and signal was detected using 
ImageQuant LAS 4000 (GE Healthcare, Glattbrugg, Switzerland).
Jack bean α-mannosidase assay
Protein glucosylation state was monitored by JBαM assay as 
described in Hebert et al. (1995).
Carbonate extraction
For carbonate extraction, cells were seeded in 6-cm dishes 
(polylysine-coated) and washed in PBS and PBS-NEM. Cells were 
then resuspended in 10 mM triethanolamine, 10 mM acetic acid, 
250 mM sucrose, 1 mM EDTA, pH 7.4, and 20 mM NEM and were 
broken by four to six passages through a 1-ml, 25-gauge needle 
syringe. Nuclei were removed by 2× 1000 × g centrifugation. The 
supernatant was centrifuged at 200,000 × g in TLA-120.2 rotor for 
45 min. The supernatant obtained (cytosol) was recovered, and the 
pellet fraction was resuspended in 500 μl of 100 mM Na2CO3 and 
incubated for 25 min on ice. Samples were then centrifuged for 
45 min at 200,000 × g. The supernatant (lumen) was harvested and 
the pellet was rinsed with 500 μl of 100 mM Na2CO3 and subjected 
to further centrifugation at 200,000 × g for 35 min. The pellet was 
solubilized in RIPA on ice (20 min), and the membrane-bound 
enough to reveal a phenotype, or other factors intervene upon their 
silencing.
Retention-based quality control is alerted in the early secretory 
pathway by structural defects that may not compromise the function 
of the mutant polypeptide yet can prevent the transport of the mu-
tant polypeptide at the site of activity. Secretion of mutant polypep-
tides linked to cystic fibrosis, muscular dystrophy, idiopathic epi-
lepsy, and lysosomal storage diseases, to name only a few, can be 
promoted in cultured cells and/or in the organism by chemical or 
substrate-specific pharmacologic chaperones (Guerriero and Brod-
sky, 2012; Noack et al., 2014). The development of treatments that 
alleviate loss-of-function phenotypes caused by hampered traffick-
ing of functional yet structurally defective polypeptides has impor-
tant medical implications. It relies on the characterization of the 
mechanisms that regulate quality control and transport at the intra-
cellular or extracellular site of activity of newly synthesized polypep-
tides. The characterization of a novel, p97-regulated, DBeQ sensi-
tive quality checkpoint for native ectodomains with intramembrane 
defects highlights a novel therapeutic avenue to counter the pro-
gression of loss-of-function diseases caused by defective transport 
of functional polypeptides at their final destination.
MATERIALS AND METHODS
Expression plasmids, antibodies, and inhibitors
The pCIneo plasmids encoding for CD3δ was provided by S. Fang 
(University of Maryland Biotechnology Institute, Baltimore, MD). 
The membrane-tethered variants of α1ATc (α1ATCD3δ) and NHKc 
(NHKCD3δ; Bernasconi et al., 2010) were generated by inserting at 
the C-terminus of α1AT or NHK, both cloned in pcDNA3, residues 
97–173 of mouse CD3δ (VELDSGTMAGVIFIDLIATLLLALGVYCFA-
GHETGRPSGAAEVQALLKNEQLY QPLRDREDTQYSRLGGNWPR-
NKKS, transmembrane domain in italic). Commercially available 
purification kits (Sigma-Aldrich, Buchs, Switzerland) were used for 
DNA sample preparations. The uncharged versions of α1ATcD6A 
and NHKcD6A were produced by replacing the aspartic acid resi-
due (D) of the TM sequence (marked in bold) with alanine (A). An 
Agilent Technologies (Basel, Switzerland) mutagenesis kit was 
used to prepare the constructs. All proteins were tagged with 
hemagglutinin (HA) epitope (YPYDVPDYA), and the nucleotide se-
quences of plasmids were verified on both strands. Antibodies to 
HA, TMX1, SEL1L, derlin-1 were obtained from Sigma-Aldrich; 
antibodies to CNX, GP78, HRD1, HERP, derlin-2 and UGGT1 were 
kind gifts of A. Helenius (ETH, Zurich, Switzerland), S. Fang and 
R. Wojcikiewicz (SUNY- Upstate Medical University, Syracuse, NY), 
K. Kokame (Cerebral and Cardiovascular Center, Osaka, Japan), Y. 
Ye (National Institutes of Health, Bethesda, MD), and A. Parodi 
(Fundación Instituto Leloir, Buenos Aires, Argentina), respectively. 
KDEL (BiP-GRP94) was provided by Stressgen (Lausen, Switzer-
land), BAP31 by Alexis Biochemicals (Lausen, Switzerland), βCOP 
by ABR (Lausen, Switzerland), and ubiquitin by DAKO (Baar, 
Switzerland). PS-341 (Millennium Pharmaceuticals, Cambridge, 
MA), DBeQ, CST, and apyrase (all from Sigma-Aldrich) were used 
at final concentrations of 10 μM, 10 μM, 1 mM, and 18 U/ml, 
respectively.
Cell lines, transient and stable transfections, 
and RNA interference
HEK293 cells were grown in DMEM/10% fetal bovine serum (FBS). 
Transfections were performed with Lipofectamine 2000 (Invitrogen) 
according to the instructions of the manufacturer. For generation of 
stable cell lines, cells were selected for 2 wk in DMEM supplemented 
with 10% FBS and 2% Geneticin. RNA interferences were performed 
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fraction was rescued after further centrifugation for 10 min at 
200,000 × g. Normalized quantities of fractions were loaded on 
SDS–PAGE and transferred on PVDF membranes, and immunoblot 
was performed as previously described.
Indirect immunofluorescence microscopy
Stable HEK293 cells were plated 17 h before fixation on polylysine-
coated coverslips. Cells were washed twice with PBS and fixed at 
room temperature for 20 min with 3.7% formaldehyde diluted in 
PBS. Cells were washed (3× 5 min) with PBS and incubated in per-
meabilization solution (0.1% Triton X-100 in PBS) for 15 min to im-
prove antigen accessibility. Washings in PBS (3× 5 min) were per-
formed before 30-min incubation with 10% FBS diluted in PBS 
(blocking solution). Cells were incubated for at least 1 h, 30 min with 
primary antibodies diluted 1:50 to 1:100 in blocking solution, 
washed three times (PBS), and incubated with Alexa Fluor–conju-
gated secondary antibodies (Invitrogen) diluted 1:200 in blocking 
solution for at least 45 min. Cells were rinsed with PBS (three 
for 5 min each) and H2O and mounted with Vectashield (Vector 
Laboratories) supplemented with 4′,6-diamidino-2-phenylindole. 
Images were collected using a laser scanning confocal microscope 
(Leica DI6000 microscope stand connected to a SP5 scan head). 
ImageJ software (National Institutes of Health, Bethesda, MD) was 
used for image analysis and processing.
Cross-linking assay
HEK293 cells were seeded in 3.5-cm polylysine-coated dishes 17 h 
before treatment. Immediately before use, DSP (Sigma-Aldrich) was 
prepared at 100× final concentration in dimethyl sulfoxide. Cells 
were washed once with PBS and incubated for 30 min at room tem-
perature in PBS supplemented with 1 mM DSP. The reaction was 
quenched by incubating cells with PBS and 20 mM Tris, pH 7.8, for 
15 min.
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